MedTrace Logo

"Mulligan Technique vs Phonophoresis With Chitosan for Patellofemoral Pain"

NCT07445607 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-03-03

No results posted yet for this study

Summary

Patellofemoral pain syndrome (PFPS) is a common knee condition causing pain and dysfunction. This study aims to compare the effectiveness of two physical therapy treatments for PFPS: Mulligan mobilization with movement technique versus phonophoresis with chitosan gel.

Forty-five participants with patellofemoral pain syndrome will be randomly assigned to one of three groups: (1) Mulligan technique group, (2) Phonophoresis with chitosan gel group, or (3) Control group receiving standard physical therapy exercises. Each group will receive treatment 3 times per week for 4 weeks.

The researchers want to determine which treatment is more effective in improving neuromuscular control, reducing pain, and improving function in patients with patellofemoral pain syndrome. Participants will be assessed before and after the treatment period.

This study may help physical therapists and healthcare providers choose the most effective treatment approach for patients with patellofemoral pain.

Conditions

  • Patellofemoral Pain Syndrome

Interventions

PROCEDURE

Mulligan technique

Each mobilization with movement (MWM) is performed in three sets of 10 repetitions, with a 30-second rest interval between sets, 3 times per week for 6 weeks, before hip and knee strengthening exercises.

PROCEDURE

Phonophoresis with Chitosan Gel

Phonophoresis (ultrasound with chitosan gel) is applied at 1 MHz, 1.0 W/cm², continuous mode, for 5 minutes, 3 times per week for 6 weeks before hip and knee exercises.

BEHAVIORAL

Standard Physical Therapy Exercise Program

Participants attend 3 sessions per week for 6 weeks. Each session includes stretching and hip and knee focused exercises. Progression involves weekly increases in repetitions and resistance based on pain levels (less than 3/10).

Sponsors & Collaborators

  • Ahram Canadian University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-15
Primary Completion
2026-07-31
Completion
2026-08-31

Countries

  • Egypt

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07445607 on ClinicalTrials.gov